Theracryf Plc · LSE:TCF
Theracryf — Evgen Pharma — Shareholder Meeting (July 2021)
13 slides from Theracryf's shareholder meeting presentation, Jul 13, 2021
Slide 1: Evgen Pharma plc: Harnessing the Power of Sulforaphane, 2021 AGM
EVGEN PHARMA PLC Harnessing The Power of Sulforaphane 2021 AGM 1
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB
Slide 3: Evgen - A Clinical Stage Drug Development Company
Evgen - A Clinical Stage Drug Development Company Focus on breast cancer, glioma and other cancers, SFX-01 has three molecular targets - STAT 3, Nrf2 and SHP2 ▪ Semi-virtual, listed on AIM (LSE: EVG), focus: cancer and inflammation ▪ 275m shares in issue, market cap c.£14m, prior range £27m to £11m
Slide 4: 2020/21 Achievements
2020/21 Achievements mBC Promising Phase 2a clinical data. Pre-clinical data from collaboration with University of Manchester and The Christie Hospital suggests SFX-01 may be effective in CDK4/6 resistant patients. GLIOMA Powerful pre-clinical data including significant survival benefit from Univers
Slide 5: Management and Board
Management and Board Extensive commercial, regulatory, clinical CMC/Manufacturing, business development expertise and a successful commercial track record Dr Huw Jones, Richard Moulson, Dr Helen Kuhlman, Dr Glen Clack, CEO CFO CBO CMO Over 30 years’ experience of leadership in Chartered accountant w
Slide 6: Scientific Advisors
Scientific Advisors Dr Mary Stuart Dr Sacha Howell Professor Anthony Chalmers Professor Rob Clark Consultant, Breast Cancer Professor of Breast Biology, Chair of Clinical Oncology at Consultant Medical Oncologist at University of Glasgow: Programme University of Manchester Christie Foundation Trust
Slide 7: Pipeline Progress, Benchmark Value, Plan
Pipeline Progress, Benchmark Value, Plan SFX-01 Discovery Pre-clinical Phase 1 Phase 2a Partnering FY 2021/22 POC Pipeline Market Milestones average* ProgressIn vivoSFX- pre-clinical ER+ve Breast Cancer 01 $19m up front, data in CDK 4/6 $144m total resistance. Phase 2b design. Orphan drug Glioma $11
Slide 8: SFX-01 Can Be Life-changing
SFX-01 Can Be Life-changing ▪ Diagnosed age 40 ER+ Her2- early Breast Cancer ▪ Received surgery, chemotherapy and tamoxifen ▪ After 5 years diagnosed with pleural nodules ▪ Enrolled into Phase 2a trial May 2017 – tamoxifen + SFX- 01 ▪ Objective response to treatment, very well tolerated, able to con
Slide 9: Glioblastoma (GBM)
Glioblastoma (GBM) ▪ Very poor life expectancy, average time to death after diagnosis 14 months, 5% five-year survival. Current treatments include surgical resection, radiotherapy and chemotherapy, frequent relapses. ▪ In US GBM accounts for 57% of gliomas, with circa 11,500 diagnosed per annum* ▪ I
Slide 10: Glioma cell line data: MDA-MB-231 (TNBC), A375 (melanoma)
Dr Euphemia Leung, Prof Bruce Baguley –University of Auckland: low passage glioma (and other) cell lines Monolayer Spheroid 20 60 SFX01 SFX01 SFN SFN 15 40 IC50 (mM) IC50 (mM) 10 20 5 0 0 NZB9 NZB11 NZB13 NZB18 U87mg U251 A375 (melanoma) H460 (lung) MDA-MB-231 (TNBC) HCT116 (colon) NZB9 NZB11 NZB13
Slide 11: Glioblastoma next steps
Glioblastoma next steps ▪ Further in vivo work at a CRO to build upon the subcutaneous GBM tumour model experiments conducted by Aquila. ▪ Orphan Drug Application submitted to FDA ▪ Plans for a Phase II GBM clinical trial with an adaptive design are progressing. IND being prepared for submission to
Slide 12: Summary
Summary ▪ Semi-virtual, listed on AIM (LSE: EVG), focus: cancer and inflammation ▪ Granted IP on SFX-01 and analogues ▪ Exciting pre-clinical data in multiple cancers, Glioblastoma, BC, JMML ▪ Positive Phase 2 clinical data in breast cancer ▪ Multiple value inflection points, licensing deals in our
Slide 13: Evgen Pharma plc
Evgen Pharma plc www.evgen.com Contact: enquiries@evgen.com Dr Huw Jones, CEO Richard Moulson, CFO finnCap Geoff Nash gnash@finncap.com Edward Whiley ewhiley@finncap.com